Key result
Radiofrequency renal denervation linked to marked office SBP reductions across high-risk patient subgroups.
Why the study?
Prospective data on the efficacy of renal denervation in predefined high cardiovascular risk populations with uncontrolled diabetes, severe CKD, and isolated systolic hypertension are limited due to their exclusion from recent trials.
Does radiofrequency renal denervation reduce office systolic blood pressure in patients with high cardiovascular risk (diabetes mellitus, severe chronic kidney disease, and/or isolated systolic hypertension)?
Observational (n=210)
Yes
Does radiofrequency renal denervation reduce office systolic blood pressure in patients with high cardiovascular risk (diabetes mellitus, severe chronic kidney disease, and/or isolated systolic hypertension)?
Answers are grounded in this paper and cite their sources.
Radiofrequency renal denervation safely and effectively lowers blood pressure at 6 months in patients with uncontrolled hypertension and severe comorbidities like diabetes, moderate CKD, or isolated systolic hypertension.
Hypertension is the most prevalent risk factor for cardiovascular (CV) disease, often coexisting with diabetes mellitus (DM) and chronic kidney disease (CKD), which are associated with heightened sympathetic activity and increased CV mortality.1 Although blood pressure (BP) control in these high-risk populations improves outcomes, nonadherence to antihypertensive medications remains a significant barrier to optimal control. Renal denervation (RDN) lowers BP independent of medication adherence.2 However, prospective data in predefined high-risk populations remain limited, especially in patients with uncontrolled DM, severe CKD, and isolated systolic hypertension (ISH), because these populations were excluded from recent RDN trials.
No takes yet. Share an insight, caveat, or question.
Mahfoud et al. (2026) conducted an observational in Uncontrolled hypertension with high cardiovascular risk (n=210). Radiofrequency Renal Denervation was evaluated on Office systolic blood pressure change at 6 months compared with baseline (p=<0.0001). Radiofrequency renal denervation significantly reduced office systolic blood pressure at 6 months from baseline in high cardiovascular risk patients with diabetes (-13.3 mm Hg), chronic kidney disease stage 3b (-19.3 mm Hg), or isolated systolic hypertension (-10.6 mm Hg).
Synapse has enriched 10 related papers. Consider them for comparative context: